Neurologist practice patterns in treatment of muscle cramps in Canada
© Lim Fat et al.; licensee BioMed Central Ltd. 2013
Received: 27 November 2012
Accepted: 18 December 2012
Published: 9 January 2013
Recently an article provided patient perspectives on therapies and perceived effectiveness in preventing muscle cramps. However, there are few studies evaluating physicians’ point of view in the management of this common symptom. In our study, we studied physician practice patterns in the treatment of muscle cramps by surveying a group of neurologists in Canada. We demonstrated that most physicians use a combination of pharmacological and non-pharmacological methods in treating muscle cramps. The most commonly used medications are baclofen, quinine and gabapentin, of which baclofen and quinine were reported to be the most tolerated.
KeywordsMuscle cramps Baclofen Quinine Practice parameters
We read with great interest the article written by Blyton et al. evaluating patient experience of treatments for muscle cramps . In 2010, we presented a review of existing literature on the treatment of muscle cramps , however, there have been few publications that bridge the gap between evidence-based medicine and clinical practice as this article does. In this commentary, we present additional data on the practice patterns of a group of Canadian neurologists in the management of muscle cramps in an effort to further connect this gap.
Non-pharmacological and pharmacological agents used by neurologists (n = 54) in the treatment of muscle cramps, as well as the percentage of physicians who used each particular agent
Number of physicians prescribed, n (%)*
Number of physicians rating agent as most tolerable, n (%)*
Quinine and its derivatives
Prescription-grade quinine appears to be one of the most effective medications for cramps according to neurologists in our study and “quite effective-100% effective” in 14/18 patients in the Blyton study. Cramp away or crampeze in contrast, which contain much lower amounts of quinine than the 300 mg of quinine used in most trials, is found to be useless or of little help most of the time. This type of data is important to patients and physicians, as prescription guidelines for quinine are country specific. The FDA (USA) and TGA (Australia) have banned the marketing of quinine derivatives for muscle cramps [3, 4]. Although the intention of our questionnaire was not to identify adverse events associated with quinine, it does show that prescription-strength quinine continues to be prescribed frequently and with good tolerability in Canada. Other published reviews have supported the use of quinine derivatives for short-term administration (under 60 days)  and in the physician-supervised treatment of disabling cramps .
Both studies reported the frequent use of non-pharmacological agents in the management of muscle cramps, most commonly stretching and hydration. Although these interventions had limited perceived efficacy according to patients, the low risk makes them good options as first-line recommendations. A comprehensive list of over-the-counter and homeopathic treatments was presented in the Bylton paper. Although magnesium is used frequently by patients, we agree that it has a limited role in treating muscle cramps outside the setting of pregnancy. None of the physicians in our survey used magnesium and our review found no evidence for their use in idiopathic muscle cramps . Information gathered in our survey also supplements the Blyton article, which presented limited data on prescriptions medications. Medications other than quinine included baclofen (used most frequently and with best tolerability), gabapentin, calcium channel blockers, clonazepam, diazepam, and mexilitine. Of all these medications, only calcium channel blockers have modest evidence for use in cramps .
There are methodology limitations in both questionnaire-based studies, including recall bias, limited information on side effects and etiologies of cramps, including medications .
Although caution needs to be used in interpreting these results, we hope that they will provide information relevant to clinical practice as serve as a catalyst for additional case–control and treatment trials for muscle cramps.
Our study shows that a combination of pharmacological and non-pharmacological methods was employed in treating muscle cramps. Moreover, physicians turn to baclofen, quinine and its derivatives, and gabapentin for pharmacological agents.
Food and Drug Administration
Therapeutics Good Association.
- Blyton F, Chuter V, Burns J: Unknotting night-time muscle cramp: a survey of patient experience, help-seeking behaviour and perceived treatment effectiveness. J Foot Ankle Res. 2012, 5: 7-10.1186/1757-1146-5-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Katzberg HD, Khan AH, So YT: Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2010, 74 (8): 691-696. 10.1212/WNL.0b013e3181d0ccca.View ArticlePubMedGoogle Scholar
- Food and Drug Administration: Department of Health and Human Services. Drug products containing quinine; enforcement action dates. Fed Regist. 2006, 71: 75557-75560.Google Scholar
- Quinine indications - cramps deleted. Aust Adv Drug React Bull. 2004, 23:
- El-Tawil S, Al Musa T, Valli H, Lunn MP, El-Tawil T, Weber M: Quinine for muscle cramps. Cochrane Database Syst Rev. 2010, 8: 12-Google Scholar
- Garrison SR, Colin RD, Morrow RL, Carney GA, Khan KM: Nocturnal leg cramps and prescription use that precedes them: A sequence symmetry analysis. Arch of Int Med. 2012, 172: 120-126. 10.1001/archinternmed.2011.1029.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.